Company advancing ZB-168, an anti-IL7R monoclonal antibody, originally developed by Pfizer Inc., in multiple phase 2 clinical trials The transaction values the combined companies at a pro forma
To accelerate clinical development of its best-in-class and first-in-class immuno-oncology programs Domain Therapeutics, a biopharmaceutical company specializing in the research and development of